Notably, in line with previous reports [22, 24], co-treatment with the CHK inhibitor PF-0477736 enhanced the efficacy of doxorubicin in the TP53 mutant DLBCL cell lines (Figure S2A). This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.